CO:08:5 | Clinical impact of anti-Ro52 antibodies in idiopathic inflammatory myopathies: insights from a multicenter Italian cohort: Paola Bizioli1, Cesare Tomasi2, Francesca Bellisai3, Francesca Buzzulini4, Antonio Tonutti5|6, Angela Ceribelli5|6, Edoardo Conticini3, Anna Ghirardello7, Luca Iaccarino7, Danilo Villalta4, Franco Franceschini1, Ilaria Cavazzana1. | 1Rheumatology and Clinical Immunology Unit - ERN ReCONNET, ASST Spedali Civili of Brescia; 2Department of Clinical and Experimental Sciences, University of Brescia; 3Department of Medicine, Surgery and Neurosciences, Rheumatology Unit, University of Siena; 4Department of Laboratory Immunology and Allergology, Santa Maria degli Angeli Hospital, Pordenone; 5Department of Biomedical Sciences, Humanitas University, Rozzano (MI); 6Rheumatology and Clinical Immunology, Istituti di Ricovero e Cura a Carattere Scientifico, Humanitas Research Hospital, Rozzano (MI); 7Division of Rheumatology, Department of Medical and Surgical Sciences, University of Padova, Italy. Reumatismo [Internet]. 2025 Nov. 25 [cited 2026 Jul. 7];77(s1). Available from: https://www.reumatismo.org/reuma/article/view/1984